Highlights
-
CIRT should be reported similarly to initiate international trials
-
Different uncertainties affect dose-effect relationship throughout CIRT planning
-
Equieffective dose and target volume definition and application require particular attention
-
We propose some suggestions to harmonize the practices
Background
The ULICE project
Methods
∙ Institution/name | |
∙ Equipment | |
o type of accelerator, | |
o energy, | |
o beam delivery system, | |
∙ Treatment setup | |
o patient position: lying, sitting, | |
o immobilization, fixation device(s) used | |
o methods used to ensure positioning reproducibility | |
o methods used for recording patient positioning: XR, scan | |
o image fusion (if used): technique, recording | |
∙ Delineation procedure | |
o procedure for CTV(s) delineation | |
o safety margins added around the CTV to define the PTV and to ensure its proper coverage | |
o do you proceed separately for each beam to add the above-mentioned margins? | |
o procedure for dose prescription/specification to the CTV-PTV | |
o procedure for dose limitation/specification to OARs | |
∙ Beam delivery | |
o one single fixed beam | |
o several fixed beams | |
o scanning beam | |
∙ Dosimetry | |
o biological plan optimization | |
o beam dosimetry: calibration, homogeneity | |
∙ Procedure for control and validation of the treatment plan before application to the first session | |
∙ What kind of record are stored at the end of the treatment? |
Results
Country | Institution | A Pt Statistics | B Equipment | C Positioning and immobilization devices | D Definition of the target volumes | E Prescription schedule(s) and dose constrains to OARs | F Treatment planning system and dose calculation | G Beam delivery system and positioning control | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Opening date | Total patients treated (per nov 2017) | Ion source | Injector | Type of accelerator, diameter | Manufacturer | Max C ions energy (MeV/u) | Max beam Intensity (C/spill) and Repetition rate (Hz) | Max field size | Treatment room(s) | Patient position | Immobilization device | Image fusion? | GTV definition | Procedure for CTV(s) delineation | CTV-PTV margin | Portal-specific PTV? | Treatment schedule | Dose unit reported in the original protocol | Dose prescription for PTV | Dose constraints for OAR | TPS | Biological modeling | Beam delivery System | Beam energy | Methods to ensure positioning reproducibility | ||
Japan | Chiba (HIMAC) pilot facility | 1994 | 10,692 | 10 GHz Kei2 ECR, 18 GHz ECR & PIG | RFQ + Alvarez linac | Dual synchrotron, 42 m | Research machine | 400 | 1.2 × 10^9 0.3 Hz | 22 cm | 3 (1H, 1 V, 1H&V) | Lying (Supine position) | Customized cradles (Moldcare®), thermoplastic mask, Vacuum bags for the body | 2D to 2D | T1 post gadolinium and T2 (fat sat or Flair fat sat) | CTV1 = CTV2: minimum margin of 5 mm around the pre-op GTV. Only one CTV and one dose level applied | 2–3 mm | yes | B | GyE | 16 fractions, 4 days a week over 4 weeks. The target reference point dose is defined as the isocenter, and the PTV is encompassed by the minimum 90% dose line of the reference point dose. | Brain stem: Dmax ≤30 Gy EQD; Optic pathway: Dmax ≤40 Gy EQD; Temporal lobe: V50 ≤ 5 cc | Xio-N (ELEKTA and Mitsubishi Electric, Tokyo, Japan) + K2DOSE; | Biological adjustment with HSG cell line Modified MKM | passive conventional and spiral beam wobbling | 290–400 | Orthogonal X-ray images |
Chiba (HIMAC) new facility | 2011 | Toshiba | 430 | 6 × 10^9 0.3 Hz | 22 cm (gantry: 20 cm) | + 3 (2H&V, 1 gantry) | active Pencil-beam 3D scanning | 290–430 | |||||||||||||||||||
Gunma (GHMC) | 2010 | 2231 | 10 GHz KeiGM ECR | RFQ + APF linac | Synchrotron, 20 m | Mitsubishi Electric | 400 | 1.2 × 10^9 0.5 Hz | 15 cm | 3 (1H, 1H&V, 1 V) | Lying (supine, prone, or lateral) position with rolling depending on tumor location and beam direction | 2D to 2D | CTV1: pre-op GTV + a margin of 3-5 mm including suspected subclinical disease CTV2: same as GTV visible on MRI | 2 mm | no | Passive (Single or Spiral Wobbling), Layer-Stacking technique available | 290–400 | ||||||||||
Germany | Darmstadt (GSI) | 1998–2009 | 440 | 14.5 GHz CAPRICE ECR | RFQ+ IH-DTL + Alvarez (UNILAC) | Synchrotron, 20 m | Research machine | 430 | 1 × 10^8 0.1–0.5 Hz | 20 cm | 1H | / | / | / | / | / | / | / | CGE | / | / | / | / | active raster scanning, intensity modulated | / | / | |
Heidelberg (HIT) | 2009 | 2430 | 14.5 GHz Supernanogan ECR ×2 | RFQ+ IH-DTL linac | Synchrotron, 20 m | GSI and Siemens | 430 | 1 × 10^9 0.3 Hz | 20 cm | 3 (2H, 1 gantry) | Lying (Supine position) | Thermoplastic mask and individual mouthpiece | 2D to 2D and 2D to 3D | CTV1 (primary plan): pre-op GTV + whole clivus + prevertebral muscles down to C2 CTV2 (Boost plan): postop GTV + 2 mm | 3 mm | no | A | Gy_E | 22 fractions, 5 (MIT) or 6 (HIT) days a week over 3.5–4.5 weeks; coverage of the PTV with the 95%-isodose line of the prescribed dose. Dose specification is based on equieffective dose | Optic pathways: Dmax ≤50 Gy EQD; Brainstem surface*: Dmax ≤54 Gy EQD *1% of the volume | Syngo inverse RT Planning (Siemens, Erlangen, Germany) | LEM | 50–430 | Orthogonal x-rays or cone-beam-CTs | |||
Marburg (MIT) | 2015 | 95 | 14.5 GHz Supernanogan ECR ×2 | RFQ+ IH-DTL linac | Synchrotron, 20 m | Siemens | 430 | 1 × 10^9 0.3 Hz | 20 cm | 4 (3H, 1 45 deg) | |||||||||||||||||
Italy | Pavia (CNAO) | 2012 | 816 | 14.5 GHz Supernanogan ECR ×2 | RFQ+ IH-DTL linac | Synchrotron, 24.5 m | Prototype | 480 | 4 × 10^8 0.3 Hz | 20 cm | 4 (3H, 1 V) | Lying (Supine position), if needed with head rotation | Customized rigid non-perforated thermoplastic-masks, mouth-bites and head-rests and/or moldable body-pillows | 2D-3D automatic fusion | CTV1 (low dose): pre op GTV plus 5–10 mm margins excluding optic chiasm and brainstem, but including surgical routes and prevertebral muscles. Caudal level determined on a case by case basis. CTV2 (high dose): 5 mm expansion from post op GTV, excluding brainstem and optic chiasm, including whole clivus and eventually cavernous sinus | 2 mm | no? | A or B | Gy [RBE] | Treatment planning aims to the coverage of the PTV with the 95%-isodose line of the prescribed dose. Dose specification is based on equieffective dose | Schedule A: optic pathways: Dmax ≤53 Gy EQD; brainstem: Dmax ≤55 Gy EQD; one cochlea: Dmax ≤45 Gy EQD. Schedule B: optic pathways: Dmax ≤40 Gy EQD, D20% ≤ 28 Gy EQD; brainstem: Dmax ≤35 Gy EQD; one cochlea: Dmax ≤45 Gy EQD | Syngo inverse RT Planning (Siemens, Erlangen, Germany) + RayCarbonPlanning module (RaySearch Laboratories AB, Sweden) | LEM | active raster scanning, intensity modulated | 115–400 | Optoelectronic pre-alignment with infrared reflecting beads and cameras, daily orthogonal X-ray and 2D-3D fusion; in-room optical tracking system (OTS) and patient verification system (PVS) | |
TOTAL
| 16,704 |